Product Information
HUMIRA(CF) PEN 80 MG/0.8 ML is a brand product labeled by AbbVie Inc., priced at $6731.0950 per EA under NDC 00074012402. Its NADAC has been published 158 times since Jun 21, 2023.
Manufacturer
AbbVie Inc.NDC
00074012402
Classification
Brand
Dosage Form
KIT
Last Updated
6/17/2026
Approval Type
Biologic (BLA)
FDA Application
BLA125057On Market Since
4/21/2017
Price Statistics
The NADAC for HUMIRA(CF) PEN 80 MG/0.8 ML has been published 158 times since Jun 21, 2023, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $6731.0950 per EA |
|---|---|
| All-time high | $6734.5168 (Dec 10, 2025) |
| All-time low | $6721.8790 (Jun 21, 2023) |
| 52-week high | $6734.5168 |
| 52-week low | $6729.6518 |
| Median price | $6728.5996 |
| Average price | $6727.7864 |
| Largest weekly change | +0.1% (Apr 17, 2024) |
| Weeks tracked | 158 |
| Tracking since | Jun 21, 2023 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 50% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of HUMIRA(CF) PEN 80 MG/0.8 ML?
The current National Average Drug Acquisition Cost (NADAC) for HUMIRA(CF) PEN 80 MG/0.8 ML, manufactured by AbbVie Inc., is $6731.0950 per EA (NDC 00074012402), effective Jun 24, 2026.
How has the price of HUMIRA(CF) PEN 80 MG/0.8 ML changed over time?
Over the history we have for it, the NADAC for HUMIRA(CF) PEN 80 MG/0.8 ML has held within roughly two percent of its current level. It has been tracked across 158 weekly CMS publications since Jun 21, 2023.
What are the highest and lowest recorded NADAC prices for HUMIRA(CF) PEN 80 MG/0.8 ML?
Since Jun 21, 2023, the NADAC for HUMIRA(CF) PEN 80 MG/0.8 ML has ranged from a low of $6721.8790 (Jun 21, 2023) to a high of $6734.5168 (Dec 10, 2025), with a median of $6728.5996 per EA.
Are there cheaper alternatives to HUMIRA(CF) PEN 80 MG/0.8 ML?
Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, HUMIRA(CF) 20 MG/0.2 ML SYRINGE, is $3366.1230 per EA — about 50% below HUMIRA(CF) PEN 80 MG/0.8 ML.
Who manufactures HUMIRA(CF) PEN 80 MG/0.8 ML?
HUMIRA(CF) PEN 80 MG/0.8 ML (NDC 00074012402) is labeled by AbbVie Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification